Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew Lunning, Michael Wang, Jon Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison Sehgal, Scott R. Solomon, Nilanjan Ghosh, Christine Dehner, Yeonhee Kim, Ken Ogasawara, Ana Kostic, Tanya Siddiqi

Blood (2024) 143 (5): 404–416.

https://doi.org/10.1182/blood.2023020854

Published: 2024

Includes: Supplemental data

Journal Articles

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Maria Lia Palomba, Tanya Siddiqi, Leo I. Gordon, Manali Kamdar, Matthew A Lunning, Alexandre V Hirayama, Jeremy S. Abramson, Jon E. Arnason, Nilanjan Ghosh, Amitkumar Mehta, Charalambos Andreadis, Scott R. Solomon, Ana Kostic, Ashvin Singh, Ricardo Espinola, Lily Peng, Ken Ogasawara, Amy Chattin, Michael L. Wang

Blood (2023) 142 (Supplement 1): 3505.

https://doi.org/10.1182/blood-2023-178109

Published: 2023

Journal Articles

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Pere Barba, Sally Lanar, Fei Fei Liu, Laurie Eliason, Kshawna Askew, Jennifer Devlen, Ulrika Furustrand, Ana Kostic

Blood (2023) 142 (Supplement 1): 7352.

https://doi.org/10.1182/blood-2023-178858

Published: 2023

Journal Articles

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Michael L. Wang, Leo I. Gordon, Alexandre V Hirayama, Matthew A Lunning, Ling Shi, Shien Guo, Ana Kostic, Laurie Eliason, Jinender Kumar, Maria Lia Palomba

Blood (2023) 142 (Supplement 1): 667.

https://doi.org/10.1182/blood-2023-180014

Published: 2023

Journal Articles

Nex-T TM Cluster of Differentiation 19 (CD19) Chimeric Antigen Receptor (CAR) T-Cell Therapy BMS-986353 (CC-97540): Comparative Analysis of Baseline Patient Data from Trials in Systemic Lupus Erythematosus (SLE) and Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL) Related to Manufacturability and Potential Safety

Fabian Mueller, Julie Rytlewski, Chun Wu, Sarah Hu, Ashley Koegel, Nikolay Delev, Ana Kostic, Vaishali Shah, Thomas Wegman, Georg Schett

Blood (2023) 142 (Supplement 1): 6873.

https://doi.org/10.1182/blood-2023-174276

Published: 2023

Journal Articles

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Nilanjan Ghosh, Alison R. Sehgal, Fei Fei Liu, Ana Kostic, Alessandro Crotta, Lily Peng, Marc De Benedetti, Leo I. Gordon

Blood (2022) 140 (Supplement 1): 10430–10431.

https://doi.org/10.1182/blood-2022-159686

Published: 2022

Journal Articles

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Jeremy S. Abramson, M. Lia Palomba, Leo I. Gordon, Matthew A. Lunning, Michael Wang, Jon E. Arnason, Enkhtsetseg Purev, David G. Maloney, Charalambos Andreadis, Alison R. Sehgal, Scott R. Solomon, Nilanjan Ghosh, Ana Kostic, Yeonhee Kim, Ken Ogasawara, Christine Dehner, Tanya Siddiqi

Blood (2021) 138 (Supplement 1): 2840.

https://doi.org/10.1182/blood-2021-148948

Published: 2021

Journal Articles

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Jerill Thorpe, Yue Jiang, Julie A Rytlewski, Ana Kostic, Yeonhee Kim, Leanne Peiser

Blood (2021) 138 (Supplement 1): 3834.

https://doi.org/10.1182/blood-2021-151790

Published: 2021

Journal Articles

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Jeremy S. Abramson, MD MMSc, Maria Lia Palomba, MD, Leo I. Gordon, MD, Matthew A. Lunning, DO, FACP, Michael L. Wang, MD, Jon E. Arnason, MD, Amitkumar Mehta, MD, Enkhtsetseg Purev, MD PhD, David G. Maloney, MD PhD, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, Scott R. Solomon, MD, Nilanjan Ghosh, MD PhD, Tina Albertson, MD, Jacob Garcia, MD, Ana Kostic, Daniel Li, PhD, Yeonhee Kim, Tanya Siddiqi, MD

Blood (2019) 134 (Supplement_1): 241.

https://doi.org/10.1182/blood-2019-127508

Published: 2019

Journal Articles

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Carlos R. Bachier, MD, Maria Lia Palomba, MD, Jeremy S. Abramson, MD MMSc, Charalambos Andreadis, MD MSCE, Alison R. Sehgal, MD, John Godwin, Gerhard C. Hildebrandt, MD, Tanya Siddiqi, MD, Don Stevens, MD, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, PhD, James Lymp, PhD, Tennille Thelen, Ken Ogasawara, David G. Maloney, MD PhD

Blood (2019) 134 (Supplement_1): 2868.

https://doi.org/10.1182/blood-2019-127566

Published: 2019

Journal Articles

Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Blood (2017) 130 (Supplement 1): 1495.

https://doi.org/10.1182/blood.V130.Suppl_1.1495.1495

Published: 2017

Journal Articles

Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Ranjana H. Advani, MD, Jennifer R. Brown, MD PhD, Jon E. Arnason, MD, Jeffrey A. Barnes, MD PhD, John N. Allan, MD, Stephen M Ansell, MD PhD, Susan M. O'Brien, MD, Julio C. Chavez, MD, Lieve Adriaens, PharmD, Melanie Ufkin, BS, PhD, Ana Kostic, PhD, Anne Josee Paccaly, PharmD, PhD, Bo Gao, PhD, Israel Lowy, MD PhD, David Sternberg, MD PhD, Max S. Topp, MD

Blood (2017) 130 (Supplement 1): 1550.

https://doi.org/10.1182/blood.V130.Suppl_1.1550.1550

Published: 2017

Journal Articles

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

Rajat Bannerji, MD PhD, Jennifer R. Brown, MD PhD, Ranjana H Advani, MD, Jon Arnason, MD, Susan M. O'Brien, MD, John N. Allan, MD, Julio C. Chavez, MD, Jeffrey A. Barnes, MD PhD, Robin Joyce, MD, Stephen Ansell, MD PhD, Max S Topp, MD, Lieve Adriaens, PharmD, Melanie Ufkin, PhD, Ana Kostic, PhD, Anne Paccaly, PharmD, PhD, Bo Gao, PhD, Pamela A. Trail, PhD, Israel Lowy, MD PhD, Carrie Brownstein, MD

Blood (2016) 128 (22): 621.

https://doi.org/10.1182/blood.V128.22.621.621

Published: 2016

Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

Amir T Fathi, MD, Uma Borate, MD, Daniel J. DeAngelo, MD PhD, Maureen M. O'Brien, MD, Tanya Trippett, MD, Bijal D Shah, Gregory A. Hale, MD, James M. Foran, MD, Lewis B. Silverman, MD, Raoul Tibes, MD PhD, Stuart Cramer, D.O., Melinda Pauly, MD, Stella Kim, Ana Kostic, MD, Xiaohui Huang, Yang Pan, PhD, Robert Chen

Blood (2015) 126 (23): 1328.

https://doi.org/10.1182/blood.V126.23.1328.1328

Published: 2015

Journal Articles

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Craig H Moskowitz, Michelle A Fanale, Bijal D Shah, Ranjana H Advani, MD, Robert Chen, Stella Kim, Ana Kostic, Tina Liu, Joanna Peng, Andres Forero-Torres

Blood (2015) 126 (23): 182.

https://doi.org/10.1182/blood.V126.23.182.182

Published: 2015

Journal Articles

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Craig H. Moskowitz, MD, Andres Forero-Torres, MD, Bijal D. Shah, MD, Ranjana Advani, MD, Paul Hamlin, MD, Stella Kim, MD, Ana Kostic, MD, Larissa Sandalic, MS, Baiteng Zhao, PhD, Michelle A. Fanale, MD

Blood (2014) 124 (21): 1741.

https://doi.org/10.1182/blood.V124.21.1741.1741

Published: 2014

Journal Articles

Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.

Tetsuya Nishida, MD, Ana Kostic, MD, David G. Maloney, MD, Rainer F. Storb, MD, Stanley R. Riddell, MD

Blood (2006) 108 (11): 413.

https://doi.org/10.1182/blood.V108.11.413.413

Published: 2006

NARROW

Two-year follow-up of lisocabtagene maraleucel in relapsed or refractory large B-cell lymphoma in TRANSCEND NHL 001

Lisocabtagene Maraleucel (liso-cel) in Patients (Pts) with R/R MCL: Subgroup Analyses in Pts with High-Risk Disease Features from the MCL Cohort of the TRANSCEND NHL 001 Study

Long-term Follow-up from Qualitative Interviews of Patients with Relapsed or Refractory Large B-Cell Lymphoma on Their Treatment Experience While Enrolled in a Lisocabtagene Maraleucel Study

Patient-Reported Outcomes from the MCL Cohort of the Phase 1, Seamless Design TRANSCEND NHL 001 Study of Lisocabtagene Maraleucel in Patients with R/R B-Cell NHL

Comparative Effectiveness of Lisocabtagene Maraleucel (Liso-cel) in PILOT in Patients (Pt) with Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL) for Whom Transplant Was Not Intended (TNI) Versus Conventional Second-Line (2L) Chemotherapy Regimens in the Real World

Two-Year Follow-up of Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed or Refractory (R/R) Large B-Cell Lymphomas (LBCL)

Characteristics of Post-Infusion Chimeric Antigen Receptor (CAR) T Cells and Endogenous T Cells Associated with Early and Long-Term Response in Lisocabtagene Maraleucel (liso-cel)-Treated Relapsed or Refractory (R/R) Large B-Cell Lymphoma (LBCL)

Pivotal Safety and Efficacy Results from Transcend NHL 001, a Multicenter Phase 1 Study of Lisocabtagene Maraleucel (liso-cel) in Relapsed/Refractory (R/R) Large B Cell Lymphomas

Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in Three Ongoing Clinical Studies in Relapsed/Refractory (R/R) B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Ineligible Patients: Transcend NHL 001, Outreach, and PILOT

Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies

Safety and Preliminary Clinical Activity of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-NHL Previously Treated with CD20-Directed Antibody Therapy

Phase 1 Study of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Monoclonal Antibody, in Patients with CD20+ B-Cell Malignancies Previously Treated with CD20-Directed Antibody Therapy

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Adults with Relapsed or Refractory B-Lineage Acute Leukemia (B-ALL) and Highly Aggressive Lymphoma

A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non-Hodgkin Lymphoma

Interim Analysis of a Phase 1 Study of the Antibody-Drug Conjugate SGN-CD19A in Relapsed or Refractory B-Lineage Non-Hodgkin Lymphoma

Development of Chronic Lymphocytic Leukemia (CLL) Reactive Cytotoxic T Lymphocytes after Non-Myeloablative Hematopoietic Stem Cell Transplant Correlates with Anti-Leukemia Response.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only